The present invention relates to a pharmaceutical combination that comprises an IGF1R inhibitor and an mTOR inhibitor for the treatment of cancer in a subject； a pharmaceutical composition comprising such a combination； the use of such a combination for the preparation of medicament for the treatment of cancer； a kit comprising such a combination as a combined preparation for simultaneous, separate or sequential use； and a method of treating cancer in a subject, especially a human.
